##plugins.themes.academic_pro.article.sidebar##

Download
pdf
Statistic
Read Counter : 5 Download : 1

##plugins.themes.academic_pro.article.main##

Abstract

The article presents clinical laboratory features and prognostic criteria of juvenile rheumatoid arthritis. The clinical characteristics of the disease and the results of laboratory analysis are important in choosing an effective treatment method. Medicinal and surgical treatment of joints is recommended, depending on the severity of the disease, the characteristics of the clinical flow and the results of the functional laboratory analysis.

Keywords

juvenile rheumatoid arthritis diagnostics prognosis

##plugins.themes.academic_pro.article.details##

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

How to Cite
Bobomuratov T.A., Mallaev Sh.Sh, & Mukhtorov M.G. (2024). Characteristics Of Genetic Predisposition To The Development Of Juvenile Idiopathic Arthritis In Children. Texas Journal of Multidisciplinary Studies, 38, 41–47. Retrieved from https://zienjournals.com/index.php/tjm/article/view/5809

References

  1. Wikipedia. Recombinant DNA. http:/en.wikipedia.org/wiki/Recombinant_DNA
  2. Nelson PN, Reynolds GM, Waldron EE et al. Monoclonal antibodies. Mol Pathol 2000;53(3):111–7.
  3. Wikipedia. Fusion protein. http://en.wikipedia.org/wiki/Fusion_protein
  4. Woo P. Cytokines and juvenile idiopathic arthritis. Curr Rheumatol Rep 2002;4(6):452–7.
  5. Bazzoni F., Beutler B. The tumor necrosis factor ligand and receptor families. N Engl J Med
  6. ;334(26):1717–25.
  7. Scott DL, Kingsley GH Tumor necrosis factor inhibitors for rheumatoid arthritis. N Engl J Med
  8. ;355(7):704–12.
  9. Beutler BA The role of tumor necrosis factor in health and disease. J Rheumatol Suppl 1999;57:16 –21.
  10. McDevitt H., Munson S., Ettinger R., Wu A. Multiple roles for tumor necrosis factor-alpha and
  11. lymphotoxin alpha/beta in immunity and autoimmunity. Arthr Res 2002;4(Suppl. 3 ):S 141–S152.
  12. Sfikakis PP, Kollias G. Tumor necrosis factor biology in experimental and clinical arthritis. Curr Opin
  13. Rheumatol 2003;15(4):380–6.
  14. Dekker L., Armbrust W., Rademaker CM et al. Safety of anti- TNFalpha therapy in children with
  15. juvenile idiopathic arthritis. Clin Exp Rheumatol 2004;22(2):252–8.
  16. Wilkinson N., Jackson G., GardnerMedwin J. Biologic therapies for juvenile arthritis. Arch Dis Child
  17. ;88(3):186–91.
  18. Lovell DJ, Giannini EH, Reiff A. et al. Etanercept in children with polyarticular juvenile rheumatoid
  19. arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 2000;342(11):763–9.
  20. Lovell DJ, Giannini EH, Reiff A. et al. Long-term efficacy and safety of etanercept in children with
  21. polyarticularcourse juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label,
  22. extended-treatment trial. Arthr Rheum 2003;48(1):218–26.
  23. Lovell DJ, Reiff A, Jones OY et al. Long-term safety and efficacy of etanercept in children with
  24. polyarticular-course juvenile rheumatoid arthritis. Arthr Rheum 2006;54(6):1987–94.
  25. Lovell DJ, Reiff A, Ilowite NT et al. Safety and efficacy of up to eight years of continuous etanercept
  26. therapy in patients with juvenile rheumatoid arthritis. Arthr Rheum 2008;58(5):1496–504.
  27. Giannini EH, Ilowite NT, Lovell DJ et al. Long-term safety and effectiveness of etanercept in children
  28. with selected categories of juvenile idiopathic arthritis. Arthr Rheum 2009;60(9):2794–804.
  29. Horneff G., Schmeling H., Biedermann T. et al. The German etanercept registry for treatment of juvenile
  30. idiopathic arthritis. Ann Rheum Dis 2004;63(12):1638–44.
  31. Horneff G., De Bock F., Foeldvari I. et al. Safety and efficacy of combination of etanercept and
  32. methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA):
  33. preliminary data from the German JIA Registry. Ann Rheum Dis 2009;68(4):519–25.
  34. Quartier P., Taupin P., Bourdeaut F. et al. Efficacy of etanercept for the treatment of juvenile idiopathic
  35. arthritis according to the onset type. Arthr Rheum 2003;48(4):1093–101.
  36. Eberhard BA, Ilowite NT Response of systemic onset juvenile rheumatoid arthritis to etanercept: is the
  37. glass half full or half empty? J Rheumatol 2005;32(5):763–521. Bobomuratov , T.A., Nurmatova , N.F., Sultanova , N.S., Mallaev , S.S., & Fayziev , N.N. (2022).
  38. Brestfeeding and Genetic Features of Juvenile Rheumatoid Arthritis. Journal of Pharmaceutical Negative
  39. Results, 1983-1988.
  40. Mallaev Sh.Sh , Bobomuratov TA, Fayziev NN, Sultanova NS, Dinmuxammadieva DR Genetic
  41. Aspects of Juvenile Rheumatoid Arthritis. ISSN (E): 2795 – 7624 VOLUME 10 | JULY 2022. 1-5.
  42. Mallaev Sh.Sh, Alimov A.V. Comparative effectiveness of traditional therapy and chronotherapy in
  43. the treatment of juvenile rheumatoid arthritis. // New day in medicine - 2020. - T. 1. No. 1 - P. 258-262.
  44. Mallaev Sh.Sh, Alimov A.V. Clinical course of juvenile rheumatoid arthritis and its treatment
  45. optimization // journal "Pediatrics" No. 2 Tashkent 2020. P. 200-203.
  46. Mallaev Sh . Sh ., Alimov A . IN . Clinical course of juvenile rheumatoid arthritis and its treatment
  47. optimization // Tibbiyotda yangi kun . – 2020. - №4 (32). – P. 68-71. (14.00.00. - No. 22) .
  48. Mallaev Sh.Sh. , Alimov AV Clinic - laboratory manifestation of juvenile rheumatoid arthritis //
  49. European vestnik pediatrii . – 2020. - No. 3 – P. 56-60.
  50. Mallaev Sh.Sh. Modern features of the course of clinical variants of juvenile rheumatoid arthritis //
  51. Interuniversity Scientific Congress "Higher School: Scientific Research" Moscow, 2020. - P. 64-65.
  52. Mallaev Sh.Sh. Justification of the chronopharmacological approach to the treatment of diffuse
  53. connective tissue diseases in children // Interuniversity Scientific Congress "Higher School: Scientific
  54. Research" Moscow, 2020. - P. 66-67.
  55. Mallaev Sh.Sh., Alimov A.V. Functional state of the adrenal glands in children with juvenile rheumatoid
  56. arthritis // Collection of articles based on the materials of the XXXI international scientific and practical
  57. conference No. 1 (28) Moscow 2020. - P. 76-80.
  58. Mallaev Sh.Sh., Alimov A.V. New approaches to the treatment of juvenile rheumatoid arthritis //
  59. Collection of articles based on the materials of the XXXI international scientific and practical conference
  60. No. 2 (62) Moscow 2020. - P. 18-22 .
  61. Rakhmankulova Z. Zh., Kamalov Z. S. Genetic predictors of the occurrence of hypoxic -ischemic
  62. encephalopathy in newborn children // Journal of Theoretical and Clinical Medicine. - 2020. - No. 4. - P.
  63. -101.
  64. Muxtorov MG, Yunusova RT Bolalarda C ovid-19 dan keyings davrda biriktiruvchi to'qimaning tizimli
  65. kasalliklarining laborator va clinic xususiyatlari // Journal of Academic Research of New Uzbekistan. –
  66. – T. 1. – No. 6. – pp. 33-35.
  67. Muxtorov M. et al. Biriktiruvchi to' qimaning tizimli kasalliklari bor bolalarda Covid-19 ning uchrash
  68. chastotasi //Theoretical aspects in the formation of pedagogical sciences. – 2024. – T. 3. – No. 10. – S. 149-
  69. Tilloeva , Sh Sh., Fayziyev N N. , "DIAGNOSTIC CRITERIA OF OSTEARTHROSIS IN PATIENTS
  70. OF SENIOR AGE GROUPS." EUROPEAN JOURNAL OF MODERN MEDICINE AND PRACTICE 2.9
  71. (2022): 73-77.
  72. Fayziev, N. N., Mallaev , Sh. Sh., Sultanova, N. S., & Bobomuratov , T. A. Changes in the hemostasis
  73. system in children with pneumonia and optimization of their treatment. Academic Research in Educational
  74. Sciences Volume 4 | Special Issue 1 | 2023 ISSN: 2181-1385
  75. Fayziev, N. N., Latipova , Sh. A. , NERVE SYSTEMASINING PERINATAL SHIKASTLANISH
  76. FONIDAGI OBSTRUCTIVE BRONCHITIS BOLALARDA IMMUNOLOGIK UZGARISHLAR
  77. Student Bulletin. No. 42 (140), Part 6, 2020. P. 98-101
  78. Bobomuratov T. A., Fayziev N. N., Mallaev Sh. Sh. Coronavirus infections in children, clinical features,
  79. diagnostics, treatment in children. Bulletin Tashkent medical academy № 5 2022. P. 21-23
  80. Mallaev Sh. Sh., Fayziev N. N., et al. Features of the clinical course of coronavirus infection in children
  81. (literature review) // JOURNAL OF HEPATO-GASTROENTEROLOGICAL RESEARCH. - 2022. - No.
  82. SI-2.
  83. Sultanova , NS, Avezova , GS, Mallaev , SS, & Fayziyev , NN //COMPREHENSIVE
  84. CHARACTERISTICS OF THE STATE OF HEALTH OF CHILDREN IN DIFFERENT AGE PERIODS,
  85. DEPENDING ON THE TYPES OF FEEDING AND CARE //British Medical Journal. – 2023. – T. 3. –
  86. No. 2.40. N.N. Fayziev , Sh.Sh. Mallaev , N.S. Sultanova, T.A. Bobomuratov // Changes in the system hemostasis
  87. in children with pneumonia and optimization their treatment //Academic research in educational sciences,
  88. No. 1 P 180-187
  89. Mallaev Sh Sh , NS Sultanova , GS Avezova , NN Faiziev . //Molecular-Genetic Mechanisms of the
  90. Development of Juvenile Idiopathic Arthritis in Children./ / Texas Journal of Medical Science. – 2023 31-
  91. TA Bobomuratov , NN Fayziev GENETIC FEATURES OF THE HEMOSTASIS SYSTEM IN
  92. CHILDREN WITH PNEUMONIA Bulletin of the Tashkent Medical Academy No. 9 2023. P. 29-30